Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
ACVR1 inhibitor
DRUG CLASS:
ACVR1 inhibitor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
pacritinib (3)
TP-0184 (3)
momelotinib (2)
E6201 (1)
INCB00928 (0)
pacritinib (3)
TP-0184 (3)
momelotinib (2)
E6201 (1)
INCB00928 (0)
›
Associations
(9)
News
Trials
Phase
Status
Apply
Phase
Status
Apply
Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS) (NCT06052618)
Phase 2
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Recruiting
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
02/24/2025
Initiation :
02/27/2025
Primary completion :
01/01/2033
Completion :
01/01/2034
CRP
|
Vonjo (pacritinib)
A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression (NCT02891603)
Phase 1/2
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Resear...
Completed
Phase 1/2
H. Lee Moffitt Cancer Center and Research Insti...
Completed
Last update posted :
03/25/2024
Initiation :
06/08/2017
Primary completion :
01/28/2022
Completion :
04/18/2022
IL6 • HLA-DRB1 • CD4 • HLA-B • HLA-C
|
sirolimus • Vonjo (pacritinib)
Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) (NCT02515630)
Phase 2
Sierra Oncology LLC - a GSK company
Sierra Oncology LLC - a GSK company
Completed
Phase 2
Sierra Oncology LLC - a GSK company
Completed
Last update posted :
06/19/2023
Initiation :
01/29/2016
Primary completion :
07/18/2017
Completion :
08/15/2017
CRP
|
Ojjaara (momelotinib)
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors (NCT00794781)
Phase 1
Eisai Inc.
Eisai Inc.
Completed
Phase 1
Eisai Inc.
Completed
Last update posted :
10/14/2022
Initiation :
06/22/2008
Primary completion :
08/01/2011
Completion :
10/15/2015
BRAF
|
E6201
A Single Arm, Phase Ib/II Trial of Single Agent Pacritinib in Patients With 1q21.3 Amplified Solid Tumors Enriching for Interleukin-1 Receptor-associated Kinase 1 Pathway Activation (PAIR) (NCT04520269)
Phase 1/2
National University Hospital, Singapore
National University Hospital, Singapore
Recruiting
Phase 1/2
National University Hospital, Singapore
Recruiting
Last update posted :
08/20/2020
Initiation :
07/13/2020
Primary completion :
07/01/2023
Completion :
07/01/2023
S100A8
|
Vonjo (pacritinib)
Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations (NCT02323607)
Phase 1
Bhavana Bhatnagar
Bhavana Bhatnagar
Completed
Phase 1
Bhavana Bhatnagar
Completed
Last update posted :
01/25/2019
Initiation :
01/12/2016
Primary completion :
07/12/2018
Completion :
07/12/2018
FLT3
|
FLT3 mutation
|
cytarabine • decitabine • daunorubicin • Vonjo (pacritinib)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login